BioNexus Gene Free Cash Flow Over Time
| BGLC Stock | USD 0.24 0.01 4.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out BioNexus Gene Performance and BioNexus Gene Correlation. BioNexus |
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Free Cash Flow Analysis
Compare BioNexus Gene Lab and related stocks such as Greystone Logistics, Innospec, and C Bond Systems Free Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IOSP | 188.4 M | 24.6 M | 44 M | 40.8 M | 84.4 M | 91.5 M | 88 M | 50.5 M | 74.8 M | 130.6 M | 116.2 M | 54.1 M | 39.4 M | 130.1 M | 136.6 M |
| FUL | (1.4 M) | 58.8 M | 6 M | (110.1 M) | 151.9 M | 132.4 M | 85.9 M | 185 M | 207.2 M | 244.3 M | 117.2 M | 126.5 M | 259.3 M | 298.2 M | 313.1 M |
| ALTO | (1.8 M) | (6.3 M) | (23.1 M) | 10.2 M | 75.1 M | (47.3 M) | 21.2 M | 15.6 M | (13.6 M) | (26.6 M) | 65.2 M | 10.4 M | (31.7 M) | (7.5 M) | (7.9 M) |
| GEVO | (7.2 M) | (41.6 M) | (120.5 M) | (54.8 M) | (43.9 M) | (29.6 M) | (26.5 M) | (22.5 M) | (18.1 M) | (26.8 M) | (25.2 M) | (112.4 M) | (128.4 M) | (108.2 M) | (102.8 M) |
| OEC | 139.9 M | 139.9 M | 139.9 M | 157 M | 131.3 M | 178 M | 141.8 M | 83 M | 5.8 M | 75.7 M | (19.7 M) | (69.5 M) | (151.8 M) | 173.1 M | 181.8 M |
| SNES | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.8 M) | (6.8 M) | (10.2 M) | (9.4 M) | (8.1 M) | (7.2 M) | (7.9 M) | (8.8 M) | (7.7 M) | (8.1 M) |
| LOOP | (24.5 K) | (24.5 K) | (24.5 K) | (19.7 K) | (52.4 K) | (3.3 M) | (3.3 M) | (9.2 M) | (9.6 M) | (24.8 M) | (24.8 M) | (48.1 M) | (35.9 M) | (23.7 M) | (22.5 M) |
| CRKN | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (420.6 K) | (1.7 M) | (1.7 M) | (1.1 M) | (12 M) | (12 M) | (18.3 M) | (17.4 M) |
| CMT | (4.6 M) | 2.7 M | 6.5 M | (2.4 M) | 148 K | 12.9 M | 23.2 M | 2.7 M | (12.3 M) | 9.2 M | 24.5 M | 977 K | 2.4 M | 25.7 M | 27 M |
| BCPC | 400 K | 38.3 M | 39.8 M | 47.3 M | 72 M | 61.5 M | 83.6 M | 82.5 M | 99 M | 96 M | 116.7 M | 123.1 M | 88.2 M | 145.9 M | 153.2 M |
| NEU | 447.9 M | 104.6 M | 231.4 M | 212.2 M | 155.5 M | 134.6 M | 174.4 M | 101.3 M | 132.1 M | 284.6 M | 190.8 M | 86.4 M | 59.1 M | 528.5 M | 555 M |
BioNexus Gene Lab and related stocks such as Greystone Logistics, Innospec, and C Bond Systems Free Cash Flow description
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.My Equities
My Current Equities and Potential Positions
| BioNexus Gene Lab | BGLC |
Specialization | Basic Materials, Specialty Chemicals |
| Location | Malaysia |
| Exchange | NASDAQ Exchange |
USD 0.24
Check out BioNexus Gene Performance and BioNexus Gene Correlation. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.